Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0253)
Drug Name
Cabergoline
Synonyms
Cabaser; Cabaseril; Cabergolina; Cabergolina [Spanish]; Cabergolinum; Cabergolinum [Latin]; Dostinex; Dostinex (TN); Galastop; LL60K9J05T; Sogilen; cabergoline; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 81409-90-7; BRN 6020775; C26H37N5O2; CHEBI:3286; DSSTox_CID_2719; DSSTox_GSID_22719; DSSTox_RID_76698; Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-; FCE 21336; FCE-21336; MFCD00867887; UNII-LL60K9J05T
Indication Hyperprolactinaemia [ICD11: 5A60] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 451.6 Topological Polar Surface Area 71.7
Heavy Atom Count 33 Rotatable Bond Count 8
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 4
Cross-matching ID
PubChem CID
54746
PubChem SID
10387 ; 7848050 ; 7978840 ; 8183775 ; 12013713 ; 14759961 ; 14808642 ; 34718715 ; 46508571 ; 48415679 ; 49965419 ; 53787199 ; 57313654 ; 75968790 ; 85788035 ; 92309005 ; 92713133 ; 92740959 ; 93166933 ; 103771070 ; 104305757 ; 117539013 ; 118047283 ; 126624984 ; 126656189 ; 126684133 ; 134337565 ; 135013805 ; 135652674 ; 135989394 ; 137001464 ; 142175117 ; 144206142 ; 152101006 ; 160963596 ; 162179026 ; 163133315 ; 164155372 ; 164824353 ; 170464667 ; 175267048 ; 176484246 ; 179151225 ; 184546096 ; 196111573 ; 223682255 ; 223820795 ; 226427091 ; 252222293 ; 252391240
ChEBI ID
CHEBI:3286
CAS Number
81409-90-7
TTD Drug ID
D04EGX
Formula
C26H37N5O2
Canonical SMILES
CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C
InChI
1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
InChIKey
KORNTPPJEAJQIU-KJXAQDMKSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
6-allyl-8b-carboxy-ergoline DM000515
131769949
Hydrolysis - Hydrolysis 1 [3]
FCE-21904 DM000513
9998992
Oxidation - Oxidation 1 [3]
FCE-21590 DM000514
10927015
Hydrolysis - Hydrolysis 2 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR003120 Cabergoline FCE-21904 Oxidation - Oxidation CYP3A4 [3]
MR003121 Cabergoline 6-allyl-8b-carboxy-ergoline Hydrolysis - Hydrolysis Unclear [3]
MR003119 FCE-21904 FCE-21590 Hydrolysis - Hydrolysis Unclear [3]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
References
1 Cabergoline was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
3 Clinical pharmacokinetics of cabergoline Clin Pharmacokinet. 2003;42(7):633-45. doi: 10.2165/00003088-200342070-00003.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.